Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Percutaneous Ablation Procedure
NCT06045975Phase 2Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Started Mar 2024; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06045975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045975.